Emergence of resistance to chloramphenicol among vancomycin-resistant enterococcal (VRE) bloodstream isolates

Int J Antimicrob Agents. 2004 Feb;23(2):200-3. doi: 10.1016/j.ijantimicag.2003.09.011.

Abstract

Therapeutic options for vancomycin-resistant enterococcal (VRE) bloodstream infections are extremely limited. Chloramphenicol is effective when VRE isolates are susceptible to this agent. However, longitudinal trends in chloramphenicol-resistant VRE (CR-VRE) are unknown. The possible association between CR-VRE and antibiotic use has not been studied. We analyzed the antimicrobial susceptibility profiles of all VRE blood isolates from 1991-2000 at our institution. We performed a correlational study to examine the relationship between annual hospital-wide use of specific antibiotics and antibiotic classes and CR-VRE prevalence. During the 10-year study period, the prevalence of CR-VRE increased from 0 to 11% ( P< 0.001, trend). CR-VRE prevalence was correlated only with chloramphenicol use (P=0.05 ) and quinolone use (P= 0.01 ). If these trends continue, dependence on newer, more expensive agents will increase. The correlation between both chloramphenicol use and quinolone use and the prevalence of CR-VRE suggests that efforts to preserve the utility of chloramphenicol in VRE infections may depend on optimizing the use of these agents.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteremia / epidemiology*
  • Bacteremia / microbiology
  • Blood / microbiology
  • Chloramphenicol / pharmacology*
  • Chloramphenicol / therapeutic use
  • Drug Resistance, Multiple, Bacterial*
  • Enterococcus / drug effects*
  • Enterococcus / isolation & purification
  • Gram-Positive Bacterial Infections / epidemiology
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Prevalence
  • Quinolones / therapeutic use
  • Vancomycin Resistance*

Substances

  • Anti-Bacterial Agents
  • Quinolones
  • Chloramphenicol